IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced ...
FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...
Northstrive Biosciences has received preliminary feedback from the FDA on its nonclinical studies and clinical plans for its product, EL-22, intended for use alongside GLP-1 receptor agonists in ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...
BERKELEY, Calif., Sept. 24, 2025 /PRNewswire/ -- ResVita Bio, a biotechnology company pioneering continuous protein therapy for skin diseases, today announced the successful completion of a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address ...
FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking ...
Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback